4 Stocks Dragging The Drugs Industry Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 46 points (-0.3%) at 14,513 as of Wednesday, March 27, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,149 issues advancing vs. 1,749 declining with 144 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is down 0.2%. A company within the industry that increased today was AstraZeneca ( AZN), up 0.5%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novo Nordisk A/S is down $1.94 (-1.2%) to $161.94 on average volume Thus far, 211,157 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 364,500 shares. The stock has ranged in price between $161.59-$163.25 after having opened the day at $163.25 as compared to the previous trading day's close of $163.88.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $90.6 billion and is part of the health care sector. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 0.4% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 2 analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday